Novo Nordisk (NVO.N) said the world’s first and currently only approved weekly basal insulin/GLP‑1 receptor agonist, icodec/semaglutide injection, has launched in China. The product is approved for adults with type 2 diabetes whose blood glucose remains uncontrolled on basal insulin or a GLP‑1 RA, to be used with oral glucose‑lowering drugs alongside diet and exercise.

美國副總統萬斯：關於伊朗官方媒體，有一個有趣的現象，有時其強硬派勢力會針對國內受衆極力推銷這項協議，甚至在某種程度上對協議內容進行了不實的解讀。而有時，你會看到以色列媒體中的某些勢力也會採納這些說法並加以炒作。

TrendForce says rapid growth in AI training and inference is driving data centers to higher power, density and larger-scale clusters. Rising energy use from data movement is prompting cloud service providers to elevate interconnect technology to the same strategic level as compute. Interconnect architecture has become a key determinant of AI-factory expansion speed, energy efficiency and supply-chain control. TrendForce forecasts the co‑packaged optics (CPO) and near‑packaged optics (NPO) market will jump from roughly $100 million in 2025 to more than $39 billion by 2030.